AR044491A1 - Formulaciones para tratamientos de base opioidea para el dolor, que comprenden derivados de piperazina 1-( piperidinil 1,2- disustituido) - 4 - sustituidos - Google Patents
Formulaciones para tratamientos de base opioidea para el dolor, que comprenden derivados de piperazina 1-( piperidinil 1,2- disustituido) - 4 - sustituidosInfo
- Publication number
- AR044491A1 AR044491A1 ARP040101993A ARP040101993A AR044491A1 AR 044491 A1 AR044491 A1 AR 044491A1 AR P040101993 A ARP040101993 A AR P040101993A AR P040101993 A ARP040101993 A AR P040101993A AR 044491 A1 AR044491 A1 AR 044491A1
- Authority
- AR
- Argentina
- Prior art keywords
- pain
- treatment
- opioid
- piperazine
- treatments
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 8
- 208000002193 Pain Diseases 0.000 title abstract 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940005483 opioid analgesics Drugs 0.000 abstract 3
- 239000002464 receptor antagonist Substances 0.000 abstract 3
- 229940044551 receptor antagonist Drugs 0.000 abstract 3
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 abstract 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 2
- 206010038678 Respiratory depression Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000000014 opioid analgesic Substances 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 230000020341 sensory perception of pain Effects 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Formulaciones para tratamientos de base opioidea, para el dolor y/o nocicepción, que comprenden analgésicos opioideos y derivados de piperazina 1-(piperidinil 1,2-disustituido)-4-sustituidos que tienen actividad antagonista de neuroquinina, en particular actividad antagonista del receptor de NK1, uso de dicha formulación para la manufactura de un medicamento para la prevención y/o tratamiento de la emesis, dolor y/o nocicepción, en particular en los tratamientos de dolor crónico y agudo, más particularmente para los tratamientos del dolor inflamatorio, post-operatorio, de servicio de urgencias (ER), intercurrente, neuropático y de cáncer, y uso de un antagonista del receptor de NK1 para la manufactura de un medicamento, para la prevención y/o tratamiento de la depresión respiratoria y tolerancia en los tratamientos de base opioidea para el dolor. Los antagonistas del receptor de NK1 comprenden derivados de piperazina 1-(piperidinil 1,2-disustituido)-4-sustituidos, las sales de adición de base o ácido farmacéuticamente aceptables de los mismos, las formas estereoquímicamente isoméricas de los mismos, la forma N-óxido de los mismos y profármacos de los mismos. La composición farmacéutica reduce una variedad de efectos secundarios indeseables que están asociados con los analgésicos opioides, en particular depresión respiratoria y tolerancia, aumentando de esta manera la tolerabilidad total de dichos opioides en el tratamiento del dolor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0306118 | 2003-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044491A1 true AR044491A1 (es) | 2005-09-14 |
Family
ID=33547554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101993A AR044491A1 (es) | 2003-06-10 | 2004-06-09 | Formulaciones para tratamientos de base opioidea para el dolor, que comprenden derivados de piperazina 1-( piperidinil 1,2- disustituido) - 4 - sustituidos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080070924A1 (es) |
| AR (1) | AR044491A1 (es) |
| AT (1) | ATE395062T1 (es) |
| CL (1) | CL2004001422A1 (es) |
| DE (1) | DE602004013772D1 (es) |
| ES (1) | ES2307025T3 (es) |
| MY (1) | MY137858A (es) |
| TW (1) | TW200510371A (es) |
| WO (1) | WO2004110451A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU229709B1 (en) | 2004-04-13 | 2014-05-28 | Incyte Corp Wilmington | Piperazinyilpiperidine derivatives as chemokine receptor antagonists |
| WO2006074025A1 (en) | 2004-12-30 | 2006-07-13 | Janssen Pharmaceutica N.V. | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
| ES2350647T3 (es) | 2005-03-08 | 2011-01-25 | Janssen Pharmaceutica Nv | Derivados de diaza-espiro-[4.4]-nonano como antagonistas de neuroquininas (nk1). |
| WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
| TW201105665A (en) * | 2009-04-22 | 2011-02-16 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| WO2011037771A1 (en) * | 2009-09-23 | 2011-03-31 | Merck Sharp & Dohme Corp. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| CN111557432B (zh) | 2013-02-08 | 2023-08-04 | 通用磨坊公司 | 低钠食品 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2287404A (en) * | 1994-03-15 | 1995-09-20 | Pfizer | Antiinflammatory and analgesic compositions |
| GB9426102D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
| NZ321575A (en) * | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| GB9723544D0 (en) * | 1997-11-07 | 1998-01-07 | Merck Sharp & Dohme | Therapeutic agents |
| GB9904786D0 (en) * | 1999-03-02 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| US6759520B1 (en) * | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
| GB0025354D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
-
2004
- 2004-06-07 US US10/560,482 patent/US20080070924A1/en not_active Abandoned
- 2004-06-07 DE DE602004013772T patent/DE602004013772D1/de not_active Expired - Lifetime
- 2004-06-07 AT AT04741745T patent/ATE395062T1/de not_active IP Right Cessation
- 2004-06-07 ES ES04741745T patent/ES2307025T3/es not_active Expired - Lifetime
- 2004-06-07 WO PCT/EP2004/051050 patent/WO2004110451A1/en active IP Right Grant
- 2004-06-08 CL CL200401422A patent/CL2004001422A1/es unknown
- 2004-06-08 MY MYPI20042194A patent/MY137858A/en unknown
- 2004-06-09 AR ARP040101993A patent/AR044491A1/es not_active Application Discontinuation
- 2004-06-09 TW TW093116489A patent/TW200510371A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004013772D1 (de) | 2008-06-26 |
| US20080070924A1 (en) | 2008-03-20 |
| TW200510371A (en) | 2005-03-16 |
| MY137858A (en) | 2009-03-31 |
| ES2307025T3 (es) | 2008-11-16 |
| CL2004001422A1 (es) | 2005-05-27 |
| ATE395062T1 (de) | 2008-05-15 |
| WO2004110451A1 (en) | 2004-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018862A1 (es) | Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion | |
| ECSP066990A (es) | Formulaciones con liberación controlada de principio activo que contienen vardenafilo | |
| BRPI0113331B8 (pt) | derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica | |
| CY1110495T1 (el) | Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα | |
| BRPI0513300A (pt) | forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2-propil)-fenol | |
| ATE540680T1 (de) | Pharmazeutische aripiprazol-zusammensetzungen | |
| AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
| PA8616201A1 (es) | Composiciones farmaceuticas de liberacion sostenida | |
| ECSP21022120A (es) | Administración sostenida de polipéptidos similares a la angiopoyetina 3 | |
| AR044491A1 (es) | Formulaciones para tratamientos de base opioidea para el dolor, que comprenden derivados de piperazina 1-( piperidinil 1,2- disustituido) - 4 - sustituidos | |
| AR034517A1 (es) | Formulacion farmaceutica | |
| SE0302488D0 (sv) | New combination | |
| BRPI0411290A (pt) | formulações para tratamentos da dor baseados em opióides contendo derivados substituìdos da 1,4-di-piperidin-4-il-piperazina | |
| ATE442158T1 (de) | Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form | |
| WO2004034962A3 (en) | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome | |
| IL179177A (en) | A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product | |
| AR038858A1 (es) | Combinacion | |
| UY26376A1 (es) | Combinaciones sinteticas de un antagonista de nk1 y un analogo estructural de gaba | |
| UY37412A (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos | |
| ATE460934T1 (de) | Pharmazeutische zubereitungen von ciprofloxacin | |
| MXPA05009435A (es) | Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central. | |
| AR036009A1 (es) | Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica | |
| WO2005094218A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | |
| WO2004041181A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | |
| MX2020009711A (es) | Combinacion de quinolin-4-carboxamidas y derivados de benzonaftiridina como combinacion de farmacos antipaludicos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |